Back to News
Market Impact: 0.15
Neuphoria Therapeutics Inc. Enters into Amendment No. 1 to Rights Agreement to Extend Expiration Date to October 27, 2027
Source: Nasdaq
Management & Governance
On October 23, 2026, Neuphoria Therapeutics Inc.’s board entered into Amendment No. 1 to the Rights Agreement dated October 27, 2025, with Computershare Trust Company, N.A., as rights agent. The available article text does not specify the amendment’s terms or effects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- ‘It wasn’t me, and I don’t think it was Elon’: Trump and his cabinet send mixed messages about what led to Ukraine’s Starshield interruptions
- Mark Zuckerberg owns 13% of Meta but controls 61% of its votes. California’s wealth tax would bill him on the 13%
- Volvo Cars posts Q3 loss of 3.7 billion crowns, to cut 2,500 jobs
- Expion Energy amends private placement terms, updates convertible debenture agreement
- Innventure receives Nasdaq notice for minimum bid price non-compliance
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow